Early Heart Function Check Using Echocardiography After CAR-T Cell Therapy for Blood Cancers

What this Trial Is About

Researchers are investigating the potential early heart-related side effects of CAR-T cell therapy, a new immunotherapy that modifies a patients own T lymphocytes to target cancer cells. This treatment shows promise for patients with difficult-to-treat blood cancers but can cause serious complications such as infections, cytokine release syndrome, and neurotoxicity. The study aims to estimate how often early heart problems occur after CAR-T treatment by measuring heart function changes using ultrasound. Participants will undergo transthoracic bedside echocardiography between days 3 and 5 after receiving CAR-T cells, a period when inflammatory complications are most common. Alongside ultrasound, routine tests like BNP, Troponin levels, ECG, and cytokine analyses will be done to characterize any heart toxicity and its possible link to inflammatory responses. This observational study focuses on monitoring and describing cardiac effects without administering additional treatments. During the study, participants will have heart ultrasounds before and shortly after CAR-T infusion, with follow-up assessments up to three months later. Researchers will measure changes in left ventricular ejection fraction to assess heart function and track clinical, biological, and rhythm-related signs of toxicity. The study also collects data on inflammatory biomarkers to understand the relationship between heart effects and cytokine release syndrome. Participation involves standard care procedures and monitoring to evaluate early and later heart health after CAR-T therapy.

Early Assessment of Cardiac Function After Treatment With CAR-T Cells